Table 2.
Baseline clinicopathological characteristics of 54 cases with metastatic ccRCC (cohort 2)
| Variables | Total cohort | TKI therapy group | ICI therapy group | P value | |
| No. of cases | 54 | 21 | 33 | ||
| Age, years, median (IQR) | 68 (59‒72) | 64 (59‒71) | 68 (62‒73) | 0.534 | |
| Sex, n (%) | Female | 14 (25.9) | 5 (23.8) | 9 (27.3) | 1.000 |
| Male | 40 (74.1) | 16 (76.2) | 24 (72.7) | ||
| Karnofsky performance status, n (%) | ≥80 | 50 (92.6) | 20 (95.2) | 30 (90.9) | 0.766 |
| <80 | 4 (7.4) | 1 (4.8) | 3 (9.1) | ||
| IMDC risk, n (%) | Favorable | 3 (5.6) | 2 (9.5) | 1 (3.0) | 0.239 |
| Intermediate | 32 (59.3) | 14 (66.7) | 18 (54.5) | ||
| Poor | 19 (35.2) | 5 (23.8) | 14 (42.4) | ||
| Previous nephrectomy, n (%) | 19 (35.2) | 7 (33.3) | 12 (36.4) | 1.000 | |
| Previous TKI use, n (%) | 17 (51.5) | ― | 17 (51.5) | ― | |
| Anti-CTLA4 agent use, n (%) | 11 (20.4) | ― | 11 (33.3) | ― | |
| Tissue sampling method, n (%) | Cytoreductive surgery | 23 (42.6) | 7 (33.3) | 9 (27.3) | 0.599 |
| Metastasectomy | 15 (27.8) | 7 (33.3) | 16 (48.5) | ||
| Biopsy | 16 (29.6) | 7 (33.3) | 8 (24.2) | ||
| Sarcomatoid/rhabdoid features, n (%) | Absent | 42 (77.8) | 16 (76.2) | 26 (78.8) | 1.000 |
| Present | 12 (22.2) | 5 (23.8) | 7 (21.2) | ||
| Necrosis, n (%) | Absent | 34 (63.0) | 16 (76.2) | 18 (54.5) | 0.151 |
| Present | 20 (37.0) | 5 (23.8) | 15 (45.5) | ||
| WHO/ISUP grade, n (%) | 1 | 5 (9.3) | 2 (9.5) | 3 (9.1) | 0.698 |
| 2 | 18 (33.3) | 5 (23.8) | 13 (39.4) | ||
| 3 | 18 (33.3) | 8 (38.1) | 10 (30.3) | ||
| 4 | 13 (24.1) | 6 (28.6) | 7 (21.2) | ||
| Histological phenotype, n (%) | Clear type | 15 (27.8) | 3 (14.3) | 12 (36.4) | 0.214 |
| Mixed type | 29 (53.7) | 13 (61.9) | 16 (48.5) | ||
| Eosinophilic type | 10 (18.5) | 5 (23.8) | 5 (15.2) | ||
ccRCC, clear cell renal cell carcinoma; CTLA4, cytotoxic T lymphocyte antigen 4; ICI, immune checkpoint inhibitor; IMDC, International Metastatic RCC Database Consortium; ISUP, International Society of Urological Pathology; TKI, tyrosine kinase inhibitor.